Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity

Breast cancer is the most commonly diagnosed cancer worldwide and ranks first in terms of both prevalence and cancer-related mortality in women. In this study, we aimed to evaluate the anticancer effect of mebendazole (MBZ) and radiotherapy (RT) concomitant use in triple-negative breast cancer (TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hoon Sik, Ko, Young Shin, Jin, Hana, Kang, Ki Mun, Ha, In Bong, Jeong, Hojin, Lee, Jeong-hee, Jeong, Bae Kwon, Kim, Hye Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779603/
https://www.ncbi.nlm.nih.gov/pubmed/36555137
http://dx.doi.org/10.3390/ijms232415493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779603/
https://www.ncbi.nlm.nih.gov/pubmed/36555137
http://dx.doi.org/10.3390/ijms232415493

Ejemplares similares